title: [2-(omega-phenylalkyl)phenoxy]alkylamines.II: Synthesis and selective serotonin-2 receptor binding.
abstract: A series of [2-(omega-phenylalkyl)phenoxy]alkylamines was synthesized and their receptor binding affinity was examined in vitro. These compounds showed an affinity for serotonin-2 (5-HT2) and dopamine-2 (D2) receptors. [2-(2-phenylethyl)phenoxy]alkylamine derivatives with a pyrrolidine or piperidine moiety in the structure showed higher affinity for 5-HT2 receptors but lower affinity for D2 receptors. Among these compounds, (S)-2-[2- [2-[2-(3-methoxyphenyl)ethyl]phenoxy]ethyl]-1-methylpyrrolidine, (S)-27, exhibited the most potent and selective affinity for 5-HT2 receptors. Furthermore, (S)-27 was effective in inhibiting 5-HT-induced vasoconstriction in vitro and platelet aggregation both in vitro and ex vivo.
authors.affiliation: Medicinal Chemistry Research Laboratory, Sankyo Co., Ltd., Tokyo, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Tanaka
authors.forename: R
authors.initials: R
authors.lastname: Goto
authors.forename: R
authors.initials: R
authors.lastname: Ito
authors.forename: M
authors.initials: M
authors.lastname: Hayakawa
authors.forename: A
authors.initials: A
authors.lastname: Sugidachi
authors.forename: T
authors.initials: T
authors.lastname: Ogawa
authors.forename: F
authors.initials: F
authors.lastname: Asai
authors.forename: K
authors.initials: K
authors.lastname: Fujimoto
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D001808:Blood Vessels / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007650:Ketanserin / Q000494:pharmacology; D010647:Phenyl Ethers / Q000138:chemical synthesis* / Q000494:pharmacology; D010880:Piperidines / Q000138:chemical synthesis* / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011758:Pyrroles / Q000138:chemical synthesis* / Q000494:pharmacology; D051381:Rats; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D017448:Receptors, Dopamine D2 / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism*; D044263:Receptors, Serotonin, 5-HT1; D044406:Receptors, Serotonin, 5-HT3; D012702:Serotonin Antagonists / Q000138:chemical synthesis* / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013386:Succinates / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D010647:Phenyl Ethers; D010880:Piperidines; D010975:Platelet Aggregation Inhibitors; D011758:Pyrroles; D018340:Receptors, Adrenergic, alpha-1; D011943:Receptors, Adrenergic, beta; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D044263:Receptors, Serotonin, 5-HT1; D044406:Receptors, Serotonin, 5-HT3; D012702:Serotonin Antagonists; D013386:Succinates; C064294:sarpogrelate; D007650:Ketanserin